Inspira Technologies Granted Patent in Japan for the INSPIRA™ ART System's Convertible Dual Lumen Cannula Device and Method of Use
Inspira Technologies (NASDAQ: IINN) said the Japan Patent Office granted Patent No. 7777598 on Dec 9, 2025 for its Convertible Dual Lumen Cannula and method of use, giving exclusive commercial rights in Japan through 2041.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Inspira Technologies (NASDAQ: IINN) said the Japan Patent Office granted Patent No. 7777598 on Dec 9, 2025 for its Convertible Dual Lumen Cannula and method of use, giving exclusive commercial rights in Japan through 2041.
The patent complements an earlier U.S. patent granted in 2023, creating IP protection across two major healthcare markets. The device converts a single-lumen cannula intravascularly into a dual-lumen cannula after insertion, aiming to let physicians switch modes without additional incisions. Management said this supports potential standalone disposable commercialization and integration into the INSPIRA™ ART System.
Positive
- Japan patent granted: Patent No. 7777598 (Dec 9, 2025)
- Exclusive commercial rights in Japan through 2041
- Complementary U.S. patent (granted 2023) expands IP protection
Negative
- None.
Details
News Market Reaction – IINN
On Dec 9, the day this news came out, IINN closed 4.55% above the previous close.
Data tracked by StockTitan Argus for the Dec 9 session.
Key Figures
- Shelf registration size
- $75,000,000
- Form F-3/A filed Nov 25, 2025
- Cash & equivalents
- $2.1 million
- As of June 30, 2025 (F-3/A prospectus)
- Total equity
- $1.3 million
- As of June 30, 2025 (F-3/A prospectus)
- Market cap
- $36,612,595
- Pre-news market context
- Current share price
- $1.10
- Prior to patent announcement
- 52-week range
- $0.4026 – $1.65
- Pre-news 52-week low and high
- HYLA accuracy
- 95%–99%
- HYLA blood sensor clinical study (Nov 13, 2025 news)
- Japan patent term
- Through 2041
- Dual Lumen Cannula patent protection in Japan
Historical Context
-
Expansion into larger, upgraded blood lab facilities for diagnostics.
-
Completion of HYLA non-invasive blood sensor clinical study.
-
Regulatory submission of ART100 to UAE MOHAP, expecting near-term approval.
-
Alliance to embed AI training across ART100 and HYLA platforms.
-
New VP of Global Sales and independent board member appointments.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
dual lumen cannula medical
intravascularly medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
RA'ANANA, Israel, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, announced today that the Japan Patent Office has granted Patent No. 7777598. This patent covers the Company’s novel Convertible Dual Lumen Cannula device and method of use, securing exclusive rights in one of the world’s most advanced medical device markets.
The patent grants Inspira exclusive commercial rights in the patented Dual Lumen Cannula technology in Japan through 2041. This milestone complements the Company’s existing U.S. Patent (granted in 2023), further enhancing a unified protective barrier across two of the world’s largest healthcare economies. Strategically, this IP supports the potential standalone commercialization of the cannula as a high-value disposable product, in addition to its integration into the INSPIRA™ ART System.
Inspira’s patented technology features a unique mechanism that allows a single-lumen cannula to convert into a dual-lumen cannula intravascularly, after insertion. This innovative design is engineered to allow physicians to switch modes without the need for additional incisions, potentially reducing infection risks, procedural complications, and hospital costs compared to traditional dual-lumen solutions.
“In today's market, traditional dual lumen cannulas are extremely expensive to manufacture. Our patented convertible device offers the market more affordable solution that could enhance patient safety and procedural efficiency,” said Dagi Ben-Noon, CEO of Inspira Technologies. “With proprietary protection now locked in both the U.S. and Japan, markets with some of the most demanding regulatory standards, we have solidified the foundation for both our respiratory support platforms and future disposable revenue streams.”
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s U.S. Food and Drug Administration -cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. The Company’s recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: https://inspira-technologies.com.
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the belief that the patent secures exclusive rights in one of the world’s most advanced medical device markets, that the patent enhances a unified protective barrier across two of the world’s largest healthcare economies, that the IP supports the potential standalone commercialization of the cannula as a high-value disposable product, in addition to its integration into the INSPIRA™ ART System, that the technology features a unique mechanism, that the design could potentially reduce infection risks, procedural complications, and hospital costs compared to traditional dual-lumen solutions, that the convertible device offers the market a more affordable solution that could enhance patient safety and procedural efficiency, that the Company has further solidified the foundation for both its respiratory support platforms and future disposable revenue streams. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at www.sec.gov.
Company Contact
Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.